Literature DB >> 3353051

Outpatient treatment of pelvic inflammatory disease with cefoxitin and doxycycline.

P Wølner-Hanssen1, J Paavonen, N Kiviat, M Young, D A Eschenbach, K K Holmes.   

Abstract

Sixty-three women with abdominal pain and adnexal tenderness were enrolled in a study of ambulatory treatment of acute pelvic inflammatory disease. Treatment consisted of 2 g of cefoxitin intramuscularly and 1 g of probenecid orally, followed by doxycycline, 100 mg by mouth twice daily for 14 days. Patients were stratified into groups indicating whether pelvic inflammatory disease was probable, possible, or unlikely, based upon endometrial biopsy and clinical criteria. Among 52 women who were evaluated, Chlamydia trachomatis and/or Neisseria gonorrhoeae were initially recovered from 16 (67%) of 24 with probable pelvic inflammatory disease, three (33%) of 11 with possible pelvic inflammatory disease, and three (18%) of 17 in whom pelvic inflammatory disease was considered unlikely. Of the 24 patients with probable pelvic inflammatory disease, 22 (92%) were clinically cured or improved. Of 22 patients initially infected with C trachomatis and/or N gonorrhoeae, 20 were culture-negative for both organisms after therapy. Both microbiologic failures had been reexposed. This study suggests that the combination of cefoxitin and doxycycline is effective for ambulatory treatment of pelvic inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3353051

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

Review 1.  Pelvic inflammatory disease epidemiology: what do we know and what do we need to know?

Authors:  I Simms; J M Stephenson
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

2.  Treatment of acute pelvic inflammatory disease in the ambulatory setting: trial of cefoxitin and doxycycline versus ampicillin-sulbactam.

Authors:  M Kosseim; A Ronald; F A Plummer; L D'Costa; R C Brunham
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

3.  Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?

Authors:  Gail M Trautmann; Kevin E Kip; Holly E Richter; David E Soper; Jeffrey F Peipert; Deborah B Nelson; Wayne Trout; Dianne Schubeck; Debra C Bass; Roberta B Ness
Journal:  Am J Obstet Gynecol       Date:  2008-01       Impact factor: 8.661

Review 4.  Pelvic inflammatory disease: current concepts in pathogenesis, diagnosis and treatment.

Authors:  Caroline Mitchell; Malavika Prabhu
Journal:  Infect Dis Clin North Am       Date:  2013-10-31       Impact factor: 5.982

5.  Diagnostic evaluation of pelvic inflammatory disease.

Authors:  J F Peipert; D E Soper
Journal:  Infect Dis Obstet Gynecol       Date:  1994
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.